Artemisinin Cocrystals for Bioavailability Enhancement: Part 2. In-vivo Bioavailability and PBPK Modelling

[1]  V. Yardley,et al.  Artemisinin Cocrystals for Bioavailability Enhancement. Part 1: Formulation Design and Role of the Polymeric Excipient. , 2021, Molecular pharmaceutics.

[2]  S. Basu,et al.  Use of Physiologically Based Pharmacokinetic (PBPK) Modeling for Predicting Drug-Food Interactions: an Industry Perspective , 2020, The AAPS Journal.

[3]  Ke Wang,et al.  Understanding the effects of a polymer on the surface dissolution of pharmaceutical cocrystals using combined experimental and molecular dynamics simulation approaches. , 2019, Molecular pharmaceutics.

[4]  R. Shrivastava,et al.  Current scenario of artemisinin and its analogues for antimalarial activity. , 2019, European journal of medicinal chemistry.

[5]  R. Dai,et al.  Comparison of in vitro/in vivo blood distribution and pharmacokinetics of artemisinin, artemether and dihydroartemisinin in rats , 2019, Journal of pharmaceutical and biomedical analysis.

[6]  Y. Nishimura,et al.  Editorial: Drug Repositioning: Current Advances and Future Perspectives , 2018, Front. Pharmacol..

[7]  V. Yardley,et al.  Investigating Permeation Behavior of Flufenamic Acid Cocrystals Using a Dissolution and Permeation System. , 2018, Molecular pharmaceutics.

[8]  H. Lennernäs,et al.  Physiologically Based Pharmacokinetic Model of Itraconazole and Two of Its Metabolites to Improve the Predictions and the Mechanistic Understanding of CYP3A4 Drug-Drug Interactions , 2018, Drug Metabolism and Disposition.

[9]  Ning Qiao,et al.  Insight into Flufenamic Acid Cocrystal Dissolution in the Presence of a Polymer in Solution: from Single Crystal to Powder Dissolution. , 2017, Molecular pharmaceutics.

[10]  Amitava Mitra,et al.  In Silico Modeling Approach for the Evaluation of Gastrointestinal Dissolution, Supersaturation, and Precipitation of Posaconazole. , 2017, Molecular pharmaceutics.

[11]  N. Patel,et al.  Model-Based Analysis of Biopharmaceutic Experiments To Improve Mechanistic Oral Absorption Modeling: An Integrated in Vitro in Vivo Extrapolation Perspective Using Ketoconazole as a Model Drug. , 2017, Molecular pharmaceutics.

[12]  Talia Flanagan,et al.  Approaches for Establishing Clinically Relevant Dissolution Specifications for Immediate Release Solid Oral Dosage Forms , 2017, The AAPS Journal.

[13]  Xavier Pepin,et al.  Mechanistic investigation of the negative food effect of modified release zolpidem , 2017, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[14]  Martin Bergstrand,et al.  In Vitro and In Vivo Modeling of Hydroxypropyl Methylcellulose (HPMC) Matrix Tablet Erosion Under Fasting and Postprandial Status , 2017, Pharmaceutical Research.

[15]  H. A. Portillo,et al.  Progress in imaging methods: insights gained into Plasmodium biology , 2016, Nature Reviews Microbiology.

[16]  Ke Wang,et al.  Investigating the Influence of Polymers on Supersaturated Flufenamic Acid Cocrystal Solutions. , 2016, Molecular pharmaceutics.

[17]  X. Lai,et al.  Role of polymers in solution and tablet-based carbamazepine cocrystal formulations , 2016 .

[18]  F. Kesisoglou,et al.  Application of Absorption Modeling in Rational Design of Drug Product Under Quality-by-Design Paradigm , 2015, The AAPS Journal.

[19]  Shigang S. Qiu,et al.  Effects of coformers on phase transformation and release profiles of carbamazepine cocrystals in hydroxypropyl methylcellulose based matrix tablets. , 2015, International journal of pharmaceutics.

[20]  David R. Weyna,et al.  Impact of pharmaceutical cocrystals: the effects on drug pharmacokinetics , 2014, Expert opinion on drug metabolism & toxicology.

[21]  K. Patel,et al.  Predicting the parasite killing effect of artemisinin combination therapy in a murine malaria model. , 2014, The Journal of antimicrobial chemotherapy.

[22]  C. Ockenhouse,et al.  Measurement of parasitological data by quantitative real-time PCR from controlled human malaria infection trials at the Walter Reed Army Institute of Research , 2014, Malaria Journal.

[23]  Clive G. Wilson,et al.  In vivo methods for drug absorption - comparative physiologies, model selection, correlations with in vitro methods (IVIVC), and applications for formulation/API/excipient characterization including food effects. , 2014, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[24]  Martin Bergstrand,et al.  PBPK models for the prediction of in vivo performance of oral dosage forms. , 2014, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[25]  X. Lai,et al.  Investigation of the Effect of Hydroxypropyl Methylcellulose on the Phase Transformation and Release Profiles of Carbamazepine-Nicotinamide Cocrystal , 2014, Pharmaceutical Research.

[26]  P. Chiodini,et al.  Estimating the parasitaemia of Plasmodium falciparum: experience from a national EQA scheme , 2013, Malaria Journal.

[27]  Scott L. Childs,et al.  Formulation of a danazol cocrystal with controlled supersaturation plays an essential role in improving bioavailability. , 2013, Molecular pharmaceutics.

[28]  Erik Sjögren,et al.  In silico predictions of gastrointestinal drug absorption in pharmaceutical product development: application of the mechanistic absorption model GI-Sim. , 2013, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[29]  Kairui Feng,et al.  The Simcyp Population Based Simulator: Architecture, Implementation, and Quality Assurance , 2013, In Silico Pharmacology.

[30]  Patrick Poulin,et al.  Dose Selection Based on Physiologically Based Pharmacokinetic (PBPK) Approaches , 2012, The AAPS Journal.

[31]  Gargi Mukherjee,et al.  Polymorphs, Salts, and Cocrystals: What’s in a Name? , 2012 .

[32]  C. Severini,et al.  Artemisinin and artemisinin plus curcumin liposomal formulations: enhanced antimalarial efficacy against Plasmodium berghei-infected mice. , 2012, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[33]  Sunil A Agnihotri,et al.  Recent advances and novel strategies in pre-clinical formulation development: an overview. , 2011, Journal of controlled release : official journal of the Controlled Release Society.

[34]  C. Carneiro,et al.  Plasmodium berghei NK65 induces cerebral leukocyte recruitment in vivo: an intravital microscopic study. , 2011, Acta tropica.

[35]  C. A. Morris,et al.  Review of the clinical pharmacokinetics of artesunate and its active metabolite dihydroartemisinin following intravenous, intramuscular, oral or rectal administration , 2011, Malaria Journal.

[36]  Matthew L Peterson,et al.  Improved pharmacokinetics of AMG 517 through co-crystallization part 2: analysis of 12 carboxylic acid co-crystals. , 2011, Journal of pharmaceutical sciences.

[37]  Ashwini Nangia,et al.  Solubility Advantage of Amorphous Drugs and Pharmaceutical Cocrystals , 2011 .

[38]  Lawrence X. Yu,et al.  Utility of Physiologically Based Absorption Modeling in Implementing Quality by Design in Drug Development , 2011, The AAPS Journal.

[39]  Matthew L Peterson,et al.  Improved pharmacokinetics of AMG 517 through co-crystallization. Part 1: comparison of two acids with corresponding amide co-crystals. , 2010, Journal of pharmaceutical sciences.

[40]  M. Jamei,et al.  Physiologically based mechanistic modelling to predict complex drug-drug interactions involving simultaneous competitive and time-dependent enzyme inhibition by parent compound and its metabolite in both liver and gut - the effect of diltiazem on the time-course of exposure to triazolam. , 2010, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[41]  Raimar Löbenberg,et al.  Dynamic Dissolution Testing To Establish In Vitro/In Vivo Correlations for Montelukast Sodium, a Poorly Soluble Drug , 2008, Pharmaceutical Research.

[42]  Neil Parrott,et al.  Applications of physiologically based absorption models in drug discovery and development. , 2008, Molecular pharmaceutics.

[43]  M. Karlsson,et al.  A model based assessment of the CYP2B6 and CYP2C19 inductive properties by artemisinin antimalarials: implications for combination regimens , 2008, Journal of Pharmacokinetics and Pharmacodynamics.

[44]  Ivan Nestorov,et al.  Whole-body physiologically based pharmacokinetic models , 2007, Expert opinion on drug metabolism & toxicology.

[45]  M. Lang,et al.  In vivo and mechanistic evidence of nuclear receptor CAR induction by artemisinin , 2006, European journal of clinical investigation.

[46]  Mats O Karlsson,et al.  A semiphysiological pharmacokinetic model for artemisinin in healthy subjects incorporating autoinduction of metabolism and saturable first-pass hepatic extraction. , 2005, British journal of clinical pharmacology.

[47]  M. Ashton,et al.  Artemisinin autoinduction is caused by involvement of cytochrome P450 2B6 but not 2C9 , 2003, Clinical pharmacology and therapeutics.

[48]  M. Ashton,et al.  Artemisinin Pharmacokinetics and Efficacy in Uncomplicated-Malaria Patients Treated with Two Different Dosage Regimens , 2002, Antimicrobial Agents and Chemotherapy.

[49]  K. Yuen,et al.  Improved oral bioavailability of artemisinin through inclusion complexation with β- and γ-cyclodextrins , 2001 .

[50]  B Agoram,et al.  Predicting the impact of physiological and biochemical processes on oral drug bioavailability. , 2001, Advanced drug delivery reviews.

[51]  M. Ashton,et al.  In vitro evidence for auto-induction of artemisinin metabolism in the rat , 2001, European Journal of Drug Metabolism and Pharmacokinetics.

[52]  M. Ashton,et al.  Use of saliva and capillary blood samples as substitutes for venous blood sampling in pharmacokinetic investigations of artemisinin , 2000, European Journal of Clinical Pharmacology.

[53]  H. Lennernäs,et al.  High in situ rat intestinal permeability of artemisinin unaffected by multiple dosing and with no evidence of P-glycoprotein involvement. , 1999, Drug metabolism and disposition: the biological fate of chemicals.

[54]  M. Ashton,et al.  Quantitative in vivo and in vitro sex differences in artemisinin metabolism in rat. , 1999, Xenobiotica; the fate of foreign compounds in biological systems.

[55]  L. Bertilsson,et al.  Artemisinin induces omeprazole metabolism in human beings , 1998, Clinical pharmacology and therapeutics.

[56]  M. Karlsson,et al.  Artemisinin population pharmacokinetics in children and adults with uncomplicated falciparum malaria. , 1998, British journal of clinical pharmacology.

[57]  H J Clewell,et al.  Coupling of computer modeling with in vitro methodologies to reduce animal usage in toxicity testing. , 1993, Toxicology letters.

[58]  D. L. Klayman,et al.  Qinghaosu (artemisinin): an antimalarial drug from China. , 1985, Science.

[59]  S. Kumar.  Pharmaceutical Cocrystals: An Overview , 2017 .

[60]  Organización Mundial de la Salud.  Guidelines for the treatment of malaria , 2010 .

[61]  M. Jamei,et al.  A framework for assessing inter-individual variability in pharmacokinetics using virtual human populations and integrating general knowledge of physical chemistry, biology, anatomy, physiology and genetics: A tale of 'bottom-up' vs 'top-down' recognition of covariates. , 2009, Drug metabolism and pharmacokinetics.

[62]  Kairui Feng,et al.  The Simcyp population-based ADME simulator. , 2009, Expert opinion on drug metabolism & toxicology.

[63]  J.,et al.  Drug metabolism and disposition : the biological fate of chemicals. , 1973 .